Moneycontrol PRO
HomeWorldCovid-19 spike in Asia: How dangerous is JN.1 variant and should India be worried | Key points

Covid-19 spike in Asia: How dangerous is JN.1 variant and should India be worried | Key points

What sets JN.1 apart is a unique mutation in the spike protein — the part of the virus that binds to human cells. This mutation may give the virus an edge in terms of transmissibility and immune escape.

May 19, 2025 / 21:22 IST

With COVID-19 cases on the rise across parts of Asia, particularly in densely populated Singapore, Hong Kong, China and Thailand, the attention has turned towards what is said to be the new driver behind the surge: the JN.1 variant, which is a subvariant of the Omicron lineage.

Along with its closely related descendants, JN.1 has rapidly become one of the most prevalent strains in circulation globally.

Singapore has raised its alert levels as Covid-19 cases continue to climb, with an estimated 14,200 infections reported in the week ending May 3 - up from 11,100 the previous week. Daily hospitalisations have also jumped by around 30%, prompting concern among health authorities.

In Hong Kong, officials have warned that the virus has reached a “quite high” level. Albert Au, head of the Communicable Disease Branch at the Centre for Health Protection, noted that the positivity rate in respiratory samples is now the highest in a year. The week ending May 3 saw 31 Covid-related deaths - also the highest weekly toll in a year - alongside a surge in severe cases.

What is the JN.1 variant?

COVID-19 Vaccine

Frequently Asked Questions

View more
How does a vaccine work?

A vaccine works by mimicking a natural infection. A vaccine not only induces immune response to protect people from any future COVID-19 infection, but also helps quickly build herd immunity to put an end to the pandemic. Herd immunity occurs when a sufficient percentage of a population becomes immune to a disease, making the spread of disease from person to person unlikely. The good news is that SARS-CoV-2 virus has been fairly stable, which increases the viability of a vaccine.

How many types of vaccines are there?

There are broadly four types of vaccine — one, a vaccine based on the whole virus (this could be either inactivated, or an attenuated [weakened] virus vaccine); two, a non-replicating viral vector vaccine that uses a benign virus as vector that carries the antigen of SARS-CoV; three, nucleic-acid vaccines that have genetic material like DNA and RNA of antigens like spike protein given to a person, helping human cells decode genetic material and produce the vaccine; and four, protein subunit vaccine wherein the recombinant proteins of SARS-COV-2 along with an adjuvant (booster) is given as a vaccine.

What does it take to develop a vaccine of this kind?

Vaccine development is a long, complex process. Unlike drugs that are given to people with a diseased, vaccines are given to healthy people and also vulnerable sections such as children, pregnant women and the elderly. So rigorous tests are compulsory. History says that the fastest time it took to develop a vaccine is five years, but it usually takes double or sometimes triple that time.

View more
Show

JN.1 is a sublineage of the Omicron variant, specifically descending from the BA.2.86 (Pirola) strain, which itself was known for having an unusually high number of mutations. First identified in late 2023, JN.1 quickly gained traction in several countries, including the United States, the UK, India, Singapore, and Hong Kong.

What sets JN.1 apart is a unique mutation in the spike protein — the part of the virus that binds to human cells. This mutation may give the virus an edge in terms of transmissibility and immune escape, meaning it could spread more easily and potentially evade antibodies generated by vaccines or past infections.

According to the World Health Organization (WHO), JN.1 has been designated a "variant of interest", though not yet a "variant of concern." That suggests close monitoring is underway but there's no conclusive evidence (yet) that it causes more severe illness than other Omicron subvariants.

How dangerous is JN.1?

So far, JN.1 does not appear to cause more severe disease than earlier Omicron strains. Most infections have been reported as mild to moderate, with symptoms similar to past Omicron infections: sore throat, runny nose, fatigue, cough, and fever. However, its high transmissibility is what makes it concerning.

While hospitalization rates have not dramatically spiked, older adults, the immunocompromised, and those with chronic health conditions remain vulnerable to complications.

In Singapore, health authorities have attributed the recent spike in Covid-19 infections to the LF.7 and NB.1.8 variants — both offshoots of the JN.1 sub-lineage of the Omicron strain.

Together, these two variants account for roughly two-thirds of the locally sequenced cases. Officials also suggested that the surge may be driven by waning immunity within the population.

The symptoms of these variants closely resemble those of other Covid-19 strains. Common signs include sore throat, fever, dry cough, fatigue, nasal congestion or a runny nose, headache, muscle aches, and loss of taste or smell. Some individuals may also experience conjunctivitis, diarrhoea, or mild gastrointestinal discomfort.

Do vaccines work against JN.1?

The short answer: Yes, but with reduced effectiveness.

Studies so far suggest that the updated bivalent and monovalent mRNA vaccines (like those from Pfizer-BioNTech and Moderna) still offer protection against severe illness, hospitalization, and death caused by JN.1, even if they’re less effective at preventing mild or asymptomatic infection.

This is because while JN.1 carries new mutations, its core structure still resembles that of previous Omicron strains — the target of current vaccines. Boosters, especially those updated in 2023–2024 to target newer variants, increase antibody levels that can neutralize JN.1.

Should India worry?

As of May 19, there are 257 active COVID-19 cases in India. This count stood at 93 last Friday.

Doctors in Mumbai have observed a modest rise in mild Covid-19 cases, mostly among younger people. However, there is no sign of a fresh wave. Health authorities continue to urge caution, particularly as neighbouring countries report a surge in infections.

News agency PTI quoted on Monday quoted official sources saying that the current coronavirus situation in the country was under control, even as they are keeping an eye on reports of a rise in Covid cases in Singapore and Hong Kong.

The country has a robust system for surveillance of viral respiratory illnesses, including COVID-19, through the Integrated Disease Surveillance Programme (IDSP) and ICMR. Hospitals have been asked to monitor influenza-like illnesses and severe acute respiratory infection cases.

Moneycontrol World Desk
first published: May 19, 2025 09:15 pm

Discover the latest Business News, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!

Subscribe to Tech Newsletters

  • On Saturdays

    Find the best of Al News in one place, specially curated for you every weekend.

  • Daily-Weekdays

    Stay on top of the latest tech trends and biggest startup news.

Advisory Alert: It has come to our attention that certain individuals are representing themselves as affiliates of Moneycontrol and soliciting funds on the false promise of assured returns on their investments. We wish to reiterate that Moneycontrol does not solicit funds from investors and neither does it promise any assured returns. In case you are approached by anyone making such claims, please write to us at grievanceofficer@nw18.com or call on 02268882347